Clinical trials: Central Nervous System Lesion
Gaucher Disease, Type 1, MRI
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
This study with standardized reading MRIs, will provide for the first time objective and quantified data on organomegaly (liver and spleen volumes) as well as bone alteration (Bone Marrow Burden11) of French patients treated with…
- Trial name
- EIROS (NCT03333447)
- Testing
- MRI
- Where
- France
- Volunteers
- 20 people
- Sponsor
- CEN Biotech
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
Migraine Disorders
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch.
- Trial name
- NP101-007 (NCT00724815)
- Testing
- NP101 - Sumatriptan iontophoretic transdermal patch
- Where
- 34 sites in United States
- Volunteers
- 530 people
- Sponsor
- NuPathe Inc.
Diagnostic Self Evaluation, Central Nervous System Diseases
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine.
- Trial name
- SENTIO (NCT01211873)
- Testing
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 416 people
- Sponsor
- Guerbet
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.
- Trial name
- NCT01646255
- Testing
- Rotigotine, L-dopa
- Where
- 24 sites in China
- Volunteers
- 346 people
- Sponsor
- UCB Pharma
Acute Ischemic Stroke Patients
Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.
The clinical trial is for acute ischemic stroke patients measuring cerebral oxygen saturation (rSO2) values using pulse oximeter of near-infrared spectroscopy in the frontal lesion area and normal area of brain.
- Trial name
- fNIRS (NCT06250608)
- Testing
- Pulse oximeter, NIRSITX
- Where
- 2 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- OBELAB, Inc.
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions
The purpose of this study is to evaluate the efficacy and safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); to demonstrate that, in patients requiring CNS MRI examinations, HRS-9231 is…
- Trial name
- NCT07275814
- Testing
- HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI)
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other…
- Conditions
- Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion
- Trial name
- SB-SCI-001 (NCT04812431)
- Testing
- Neural precursor cells derived from human embryonic stem cell line
- Where
- 2 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- S.Biomedics Co., Ltd.
Parkinson's Disease
A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
Evaluation of efficacy and safety on the use of rotigotine in patients suffering from Parkinson's Disease during and after surgery requiring general anaesthesia.
- Trial name
- NEUPOS (NCT00594464)
- Testing
- Rotigotine
- Where
- 12 sites in Germany
- Volunteers
- 14 people
- Sponsor
- UCB Pharma
Parkinson Disease, Idiopathic
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
Male and female patients aged ≥ 30 years with advanced stage idiopathic Parkinson's disease, not well controlled on existing levodopa will take part in a research study at approximately 82 sites in Europe, Israel, South Africa…
- Trial name
- NCT00244387
- Testing
- SPM 962
- Where
- Germany
- Volunteers
- 506 people
- Sponsor
- UCB Pharma
Skin Lesion, Traumatic Ulcer
Clinical Investigation EUCLIDES-01 for the Calculation of the Area of Skin Lesions
The aim of this clinical investigation is to collect skin lesion area data for the comparison of the agreement among the results obtained between the following three wound area measurement methods: Ruler using the Kundin method…
- Conditions
- Skin Lesion, Traumatic Ulcer, Hematoma, Pressure Ulcer
- Trial name
- NCT05729334
- Testing
- Clinicgram Euclides
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Skilled Skin S.L.
Alzheimer Disease
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
The objective of this study is to evaluate the efficacy and safety of donepezil transdermal patch in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT03197740
- Testing
- Donepezil patch, aricept Tab
- Where
- South Korea
- Volunteers
- 399 people
- Sponsor
- Icure Pharmaceutical Inc.
Migraine Disorders
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
- Trial name
- NP101-006 (NCT00720018)
- Testing
- NP101 Sumatriptan Iontophoretic Transdermal Patch
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- NuPathe Inc.
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
- Trial name
- NCT00333138
- Testing
- FTY720
- Where
- 26 sites in Canada, Denmark and 9 more
- Volunteers
- 281 people
- Sponsor
- Novartis
IDIOPATHIC PARKINSON'S DISEASE
A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
The objective of this trial is to assess the effect of rotigotine (SPM 962) on the control of early morning motor impairment and sleep disorders in subjects with idiopathic PD.
- Trial name
- NCT00243945
- Testing
- Rotigotine
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- UCB Pharma
Brain Neoplasms
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg)…
- Trial name
- NCT00681551
- Testing
- Magnevist (SH L 451A)
- Where
- 9 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Bayer